Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

NF1-PN Specialty Channel

NF1-PN
Specialty Channel

News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology
News
Selumetinib Shows Efficacy, Safety Among Pediatric and Adult Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma
07/09/2024
According to a phase 2 study, selumetinib demonstrated efficacy among both children and adults with NF1 and inoperable plexiform neurofibromas, and in other manifestations.
According to a phase 2 study, selumetinib demonstrated efficacy among both children and adults with NF1 and inoperable plexiform neurofibromas, and in other manifestations.
According to a phase 2 study,...
07/09/2024
Oncology
News
Study Findings Show Considerable Disease Burden of NF1-PN Among Affected Patients
07/01/2024
Findings from the real-world CASSIOPEA study show the considerable disease burden of neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) highlighting the importance of effective treatments for this patient population.
Findings from the real-world CASSIOPEA study show the considerable disease burden of neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) highlighting the importance of effective treatments for this patient population.
Findings from the real-world...
07/01/2024
Oncology
News
Vinblastine/Methotrexate Fails to Demonstrate Activity for NF1-PN in Pediatric and Young-Adult Patients
07/01/2024
Findings from a phase 2 study show vinblastine/methotrexate did not demonstrate activity for neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) in pediatric and young-adult patients, despite being well-tolerated.
Findings from a phase 2 study show vinblastine/methotrexate did not demonstrate activity for neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) in pediatric and young-adult patients, despite being well-tolerated.
Findings from a phase 2 study...
07/01/2024
Oncology
News
Health-Related Quality of Life Among Adult Patients With NF1-PN and Caregivers
07/01/2024
Study findings show neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) worsens adult patient and caregiver health-related quality of life vs that of the general population.
Study findings show neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) worsens adult patient and caregiver health-related quality of life vs that of the general population.
Study findings show...
07/01/2024
Oncology
News
Selumetinib for Managing NF1-PN in Pediatric Patients at Risk for Developing Tumor-Related Morbidity
07/01/2024
Among pediatric patients with neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN), treatment with selumetinib resulted in significant shrinkage in PN without any clinically significant morbidity.
Among pediatric patients with neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN), treatment with selumetinib resulted in significant shrinkage in PN without any clinically significant morbidity.
Among pediatric patients with...
07/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology
News
Selumetinib Shows Efficacy, Safety Among Pediatric and Adult Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma
07/09/2024
According to a phase 2 study, selumetinib demonstrated efficacy among both children and adults with NF1 and inoperable plexiform neurofibromas, and in other manifestations.
According to a phase 2 study, selumetinib demonstrated efficacy among both children and adults with NF1 and inoperable plexiform neurofibromas, and in other manifestations.
According to a phase 2 study,...
07/09/2024
Oncology
News
Study Findings Show Considerable Disease Burden of NF1-PN Among Affected Patients
07/01/2024
Findings from the real-world CASSIOPEA study show the considerable disease burden of neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) highlighting the importance of effective treatments for this patient population.
Findings from the real-world CASSIOPEA study show the considerable disease burden of neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) highlighting the importance of effective treatments for this patient population.
Findings from the real-world...
07/01/2024
Oncology
News
Vinblastine/Methotrexate Fails to Demonstrate Activity for NF1-PN in Pediatric and Young-Adult Patients
07/01/2024
Findings from a phase 2 study show vinblastine/methotrexate did not demonstrate activity for neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) in pediatric and young-adult patients, despite being well-tolerated.
Findings from a phase 2 study show vinblastine/methotrexate did not demonstrate activity for neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) in pediatric and young-adult patients, despite being well-tolerated.
Findings from a phase 2 study...
07/01/2024
Oncology
News
Health-Related Quality of Life Among Adult Patients With NF1-PN and Caregivers
07/01/2024
Study findings show neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) worsens adult patient and caregiver health-related quality of life vs that of the general population.
Study findings show neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) worsens adult patient and caregiver health-related quality of life vs that of the general population.
Study findings show...
07/01/2024
Oncology
News
Selumetinib for Managing NF1-PN in Pediatric Patients at Risk for Developing Tumor-Related Morbidity
07/01/2024
Among pediatric patients with neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN), treatment with selumetinib resulted in significant shrinkage in PN without any clinically significant morbidity.
Among pediatric patients with neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN), treatment with selumetinib resulted in significant shrinkage in PN without any clinically significant morbidity.
Among pediatric patients with...
07/01/2024
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement